Medical Cannabis for Chronic Pain UK — Patient Guide

Chronic pain is the most common reason UK patients seek a medical cannabis prescription through a licensed private clinic. Unlike acute pain — a short-term signal of tissue damage — chronic pain persists beyond normal healing time and often involves central sensitisation that standard analgesics struggle to address effectively.

Acute Pain vs Chronic Pain

Acute pain alerts you to injury and typically resolves as tissue heals. Chronic pain — defined clinically as pain persisting beyond three months — often involves changes in the central nervous system itself, making the pain system hyper-responsive even in the absence of ongoing tissue damage.

Chronic pain is classified by mechanism:

• Nociceptive pain: Ongoing stimulation of pain receptors from identifiable tissue damage — for example, rheumatoid arthritis or structural back pain
• Neuropathic pain: Caused by damage to or dysfunction of the nervous system — burning, shooting or electric sensations. Includes peripheral neuropathy and post-surgical nerve pain
• Nociplastic pain: Involves central sensitisation without clear peripheral pathology — fibromyalgia is the most common example

Cannabinoids and the Pain System

The endocannabinoid system is deeply integrated with pain processing. CB1 receptors are densely expressed in the dorsal horn of the spinal cord — a critical relay station where peripheral pain signals are processed before ascending to the brain. THC acts as a partial agonist at CB1 receptors, reducing pain signal transmission in the dorsal horn and modulating the emotional and affective components of pain in limbic structures. CBD does not bind directly to CB1 receptors but modulates the endocannabinoid system indirectly, with anti-inflammatory and analgesic properties. The combination of both cannabinoids — and terpenes — may produce a more complete effect than either alone.

Neuropathic pain shows the most meaningful response to cannabinoids in clinical data. Nociceptive pain is less well-evidenced, though some patients report benefit. Nociplastic pain (fibromyalgia) has a modest but consistent evidence base.

The Evidence Base: Project Twenty21

The UK's most significant real-world evidence comes from Project Twenty21, a prospective registry study run by Drug Science that enrolled over 3,000 patients prescribed medical cannabis through licensed UK clinics between 2020 and 2023.

Key findings for chronic pain patients:

• Statistically significant reductions in pain severity and pain interference scores after 1 and 3 months of treatment
• Improvements in sleep quality — sleep and chronic pain are bidirectionally reinforcing
• Reduction in use of other analgesics, including opioids, in a proportion of patients
• Most common conditions enrolled: chronic non-cancer pain, neuropathic pain, and musculoskeletal conditions

Project Twenty21 was not a randomised controlled trial — but it provides the most comprehensive UK-specific data available and is frequently cited in clinical discussions about prescribing for pain.

NICE Guidance and Chronic Pain

NICE guideline NG193 (Chronic Primary Pain, 2021) recommended against most established analgesics for chronic primary pain on the grounds that evidence of benefit is limited relative to harms. NICE TA632 reviewed cannabis-based products for chronic pain and concluded evidence was insufficient for routine NHS commissioning — but this does not prevent private specialists from prescribing on clinical grounds where other treatments have failed.

Who Qualifies

UK licensed clinics apply broadly consistent eligibility criteria for chronic pain prescriptions:

• Chronic pain lasting at least three to six months
• Evidence of a diagnosed condition (GP letter and/or medical records typically required)
• Failure of at least two prior treatments — most commonly analgesic medications (amitriptyline, gabapentin, duloxetine, NSAIDs) and/or physiotherapy
• UK residency
• Absence of significant contraindications (certain psychiatric conditions, severe cardiovascular disease, pregnancy)

See our chronic pain condition page, neuropathic pain page, and fibromyalgia page for condition-specific information.

Clinics With a Pain Focus

Several UK clinics have specialist pain consultants on their clinical teams:

• Lyphe Clinic: Large network with pain specialists, operates in London, Bristol and Glasgow.
• Releaf: Technology-led clinic with pain focus; accessible UK-wide by video.
• Zerenia: One of the UK's largest networks with pain expertise, physical locations including Glasgow.

Use our full UK clinic directory to compare all licensed providers.

Costs

Initial consultation fees range from approximately £79 to £299. Monthly medication costs typically fall between £100 and £400. For a full breakdown, see our medical cannabis cost guide.